Spinal Cord Transplant of Neural Stem Cells Can Be Safe in ALS

This article originally appeared here.
Share this content:
Spinal Cord Transplant of Neural Stem Cells Can Be Safe in ALS
Spinal Cord Transplant of Neural Stem Cells Can Be Safe in ALS

THURSDAY, June 30, 2016 (HealthDay News) -- Intraspinal transplantation of human spinal cord-derived neural stem cells appears feasible for patients with amyotrophic lateral sclerosis (ALS), but it's not yet clear whether the treatment provides any benefits, according to a study published online June 29 in Neurology.

The ALS study patients, who were from three U.S. medical centers, had first developed symptoms within the past two years. Each of the 15 patients received anywhere from 10 to 40 injections of neural stem cells into the spinal cord -- with the number of cells ranging from 2 million to 16 million.

Over nine months, most of the patients tolerated the treatment fairly well, the researchers found. The most common problems were temporary pain after the injections and side effects from immunosuppression medication. Two patients did have serious complications. "One patient developed spinal cord swelling after the surgery, and he was worse off after the procedure than before -- which is what we worried about going into this," study author Jonathan Glass, M.D., of Emory University in Atlanta, told HealthDay. The second patient developed chronic pain about a month after the procedure.

"This study provides Class IV evidence that for patients with ALS, spinal cord transplantation of human stem cells can be safely accomplished and does not accelerate the progression of the disease," the authors write. "This study lacks the precision to exclude important benefit or safety issues."

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Actemra to Treat Giant Cell Arteritis

FDA Approves Actemra to Treat Giant Cell Arteritis

New indication provides the first FDA-approved therapy specific to this type of vasculitis

Trends in Teen Binge Drinking Still Raise Concerns

Trends in Teen Binge Drinking Still Raise Concerns

Even though frequent binge drinking among adolescents has dropped in past 25 years

ATS: First Abx Rx Doesn't Work for 25 of Pneumonia Cases

ATS: First Abx Rx Doesn't Work for ~25% ...

One in four adult patients do not respond to initial prescription of antibiotic treatment

is free, fast, and customized just for you!

Already a member?

Sign In Now »